Artwork

Content provided by Oncology Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes

13:46
 
Share
 

Manage episode 420865626 series 1021077
Content provided by Oncology Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers.

At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, reported his group’s validation of the test that assesses the pattern of circulating fragments of tumor DNA, known as fragmentomes.

After discussing the findings at an AACR press briefing, Velculescu joined Peter Goodwin in the OncTimesTalk podcast studio to discuss the clinical implications.

  continue reading

156 episodes

Artwork
iconShare
 
Manage episode 420865626 series 1021077
Content provided by Oncology Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers.

At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, reported his group’s validation of the test that assesses the pattern of circulating fragments of tumor DNA, known as fragmentomes.

After discussing the findings at an AACR press briefing, Velculescu joined Peter Goodwin in the OncTimesTalk podcast studio to discuss the clinical implications.

  continue reading

156 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide